Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-536 for the Treatment of Anemia in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Previously Enrolled in Study A536-03

Next Previous
Search
Trial Profile

An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-536 for the Treatment of Anemia in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Previously Enrolled in Study A536-03

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Luspatercept (Primary)
  • Indications Anaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors Acceleron Pharma

    • Most Recent Events

    • 02 May 2020 Status changed from active, no longer recruiting to completed.
    • 05 Jun 2018 Results of erythropoietic cellular analyses from phase II base and extension study (n=49, data cut off: 8 Sep 2017; NCT01749514, NCT02268383) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 04 Jun 2018 Results published in an Acceleron Pharma Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top